Lycopene has been shown to enhance the impact of PD-1 mAb therapy, resulting in increased tumor cell death, elevated production of anti-tumor cytokines (IL-2, IFNγ), and a higher CD4+/CD8+ ratio in the spleen (178). Here, PDCD1 is linked to neoplasm.